In the search for effective COVID-19 treatments, many drugs failed to live up to their early promise. The antiviral molnupiravir performed well in trials, reducing hospitalizations and deaths among ...

This article is part of a larger series on the risks of molnupiravir. For a summary of the risks at the level of the individual, see here, and for an overview of the risks on a societal level, see ...

As coronavirus cases rage in India, Merck announced that it has entered into non-exclusive voluntary licensing agreements with five manufacturers of generic drugs in that country to speed and expand ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The antiviral reduced the risk for severe symptoms of ...

A new study suggests that the antiviral Molnupiravir may “paradoxically” be driving COVID-19 mutations, creating variants of concern. What is going on? It is all about molnupiravir’s mode of action ...

The antiviral molnupiravir may be shaping the evolution of the virus behind COVID-19, but we still don't know what this means for transmission or the emergence of variants. When you purchase through ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The investigational oral antiviral molnupiravir ...